Navigation Links
Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
Date:2/11/2011

SAN ANTONIO, Feb. 11, 2011 /PRNewswire/ -- Aperion Biologics, Inc. announced the enrollment and implantation of the first patients in the Company's clinical trial of its Z-Lig™ Anterior Cruciate Ligament Reconstruction (ACLR) Device for the treatment of ligament injuries of the knee.  The primary objective of the multicenter study is to provide additional evidence of the safety and performance of Z-Lig in the reconstruction of patients' knees with primary ACL ruptures.  Seven sites in Europe and one site in South Africa are participating in this clinical trial.  Dr. Willem van der Merwe of the Sports Science Orthopaedic Clinic in Cape Town, South Africa said, "We are pleased to be part of this cutting-edge study.  Graft options are limited for ligament reconstruction procedures and Z-Lig could prove to be a tissue alternative which would enhance the world of ACL reconstruction surgeries."  The study results will be used to support regulatory approvals and clinical acceptance of the Z-Lig ACLR device in select markets outside of the United States.

"Initiating the Z-Lig ACLR clinical trial is an important step not only for our technology and the Company but also for the field of orthopaedics," said Daniel R. Lee, Aperion Biologics' CEO.  "Z-Lig ACLR represents an opportunity to provide a biologic graft sourced from non-human tissue.  This device is a functional scaffold which supports the regeneration of the patient's own tissue.  It has been a long-standing goal for surgeons and the industry globally to have a readily available, off-the-shelf ACL graft."

The ACL is the most commonly injured knee ligament.  Over 800,000 knee ligament reconstruction surgeries are estimated to be performed each year worldwide.

Further information on the Z-Lig study is also available on www.ClinicalTrials.gov.

About  Z-Lig

Aperion's Z-Lig is a proprietary immunochemically modified porcine tissue-based, sterile medical device for implantation to reconstruct a ruptured Anterior Cruciate Ligament (ACL).  Z-Lig is the only known biological alternative to human tissue for ACL replacement in clinical evaluation.  Since Z-Lig is a biological implant that maintains a mechanically stable scaffold, it can become populated and remodeled with the patient's own cells (similar to human-sourced tissue).  Aperion previously completed a clinical study for Z-Lig in the U.S. in which the grafts successfully demonstrated safety and feasibility during the two-year evaluation.

About Aperion Biologics, Inc.

Aperion Biologics, Inc., located in San Antonio, Texas, is a privately owned, clinical-stage medical device company addressing the need for alternatives to human-based grafts with animal-based tissue technology.  Aperion has developed and patented a technique to make animal tissues usable for human applications without causing rejection.  The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both "humanizes" and sterilizes the tissues without adversely affecting their biomechanical or biological properties.  This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled.  Aperion's Z-Process™ of humanizing and sterilizing tissue is applicable to a variety of tissues used in orthopaedic, cardiovascular, plastic, dermatologic, general and other surgical specialties.

www.aperionbiologics.com


'/>"/>
SOURCE Aperion Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
2. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
3. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
4. Reportlinker Adds Immunogenicity to Biologics
5. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
6. Crescendo Biologics Announces First Triple Knockout Mouse
7. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
8. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
9. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
10. Reportlinker Adds Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 - Opportunities and Challenges in this Emerging Market With High Potential
11. Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... ... 2017 , ... Whitehouse Labs has furthered its efforts towards ... (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has more ... 2017. Extractable & Leachable evaluations have become increasingly more vital to successful product ...
(Date:1/18/2017)... Chicago, IL (PRWEB) , ... January 18, 2017 ... ... auction on January 24th, 2017, to sell research and genetic testing lab equipment ... of service in the Northwest and Northeast regions of the United States. This ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
(Date:12/15/2016)... Germany , December 15, 2016 ... provider, today announced an agreement with NuData Security, an ... forces. The partnership will enable clients to focus on good ... local data protection regulation. ... In order to provide a one-stop fraud ...
(Date:12/15/2016)... Dec 15, 2016 ... Research and Markets has announced the addition of ... The report forecasts the global military biometrics market to ... The report has been prepared based on an in-depth market analysis ... its growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):